LNF1901 / Lunan Pharma - LARVOL DELTA

Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNF1901 in the treatment of advanced malignant tumor patients (ChiCTR) - P1 | N=82 | Recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P1 trial • Solid Tumor

Phase I Study of LNF1901 in Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=82 | Not yet recruiting | Sponsor: Shandong New Time Pharmaceutical Co., LTD

Metastases • New P1 trial • Oncology • Solid Tumor